FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224616384> ?p ?o ?g. }

• W4224616384 abstract "Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug resistance aim to bring tests closer to the community, and thereby cut delay in diagnosis, ensure early treatment, and improve health outcomes, as well as overcome problems with poor laboratory infrastructure and inadequately trained personnel. Yet, diagnostic technologies only have an impact if they are put to use in a correct and timely manner. Views of the intended beneficiaries are important in uptake of diagnostics, and their effective use also depends on those implementing testing programmes, including providers, laboratory professionals, and staff in health ministries. Otherwise, there is a risk these technologies will not fit their intended use and setting, cannot be made to work and scale up, and are not used by, or not accessible to, those in need.To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance; and to identify implications for effective implementation and health equity.We searched MEDLINE, Embase, CINAHL, PsycInfo and Science Citation Index Expanded databases for eligible studies from 1 January 2007 up to 20 October 2021. We limited all searches to 2007 onward because the development of Xpert MTB/RIF, the first rapid molecular test in this review, was completed in 2009.We included studies that used qualitative methods for data collection and analysis, and were focused on perspectives and experiences of users and potential users of low-complexity NAATs to diagnose tuberculosis and drug-resistant tuberculosis. NAATs included Xpert MTB/RIF, Xpert MTB/RIF Ultra, Xpert MTB/XDR, and the Truenat assays. Users were people with presumptive or confirmed tuberculosis and drug-resistant tuberculosis (including multidrug-resistant (MDR-TB)) and their caregivers, healthcare providers, laboratory technicians and managers, and programme officers and staff; and were from any type of health facility and setting globally. MDR-TB is tuberculosis caused by resistance to at least rifampicin and isoniazid, the two most effective first-line drugs used to treat tuberculosis.We used a thematic analysis approach for data extraction and synthesis, and assessed confidence in the findings using GRADE CERQual approach. We developed a conceptual framework to illustrate how the findings relate.We found 32 studies. All studies were conducted in low- and middle-income countries. Twenty-seven studies were conducted in high-tuberculosis burden countries and 21 studies in high-MDR-TB burden countries. Only one study was from an Eastern European country. While the studies covered a diverse use of low-complexity NAATs, in only a minority of studies was it used as the initial diagnostic test for all people with presumptive tuberculosis. We identified 18 review findings and grouped them into three overarching categories. Critical aspects users value People with tuberculosis valued reaching diagnostic closure with an accurate diagnosis, avoiding diagnostic delays, and keeping diagnostic-associated cost low. Similarly, healthcare providers valued aspects of accuracy and the resulting confidence in low-complexity NAAT results, rapid turnaround times, and keeping cost to people seeking a diagnosis low. In addition, providers valued diversity of sample types (for example, gastric aspirate specimens and stool in children) and drug resistance information. Laboratory professionals appreciated the improved ease of use, ergonomics, and biosafety of low-complexity NAATs compared to sputum microscopy, and increased staff satisfaction. Challenges reported to realizing those values People with tuberculosis and healthcare workers were reluctant to test for tuberculosis (including MDR-TB) due to fears, stigma, or cost concerns. Thus, low-complexity NAAT testing is not implemented with sufficient support or discretion to overcome barriers that are common to other approaches to testing for tuberculosis. Delays were reported at many steps of the diagnostic pathway owing to poor sample quality; difficulties with transporting specimens; lack of sufficient resources; maintenance of low-complexity NAATs; increased workload; inefficient work and patient flows; over-reliance on low-complexity NAAT results in lieu of clinical judgement; and lack of data-driven and inclusive implementation processes. These challenges were reported to lead to underutilization. Concerns for access and equity The reported concerns included sustainable funding and maintenance and equitable use of resources to access low-complexity NAATs, as well as conflicts of interest between donors and people implementing the tests. Also, lengthy diagnostic delays, underutilization of low-complexity NAATs, lack of tuberculosis diagnostic facilities in the community, and too many eligibility restrictions hampered access to prompt and accurate testing and treatment. This was particularly the case for vulnerable groups, such as children, people with MDR-TB, or people with limited ability to pay. We had high confidence in most of our findings.Low-complexity diagnostics have been presented as a solution to overcome deficiencies in laboratory infrastructure and lack of skilled professionals. This review indicates this is misleading. The lack of infrastructure and human resources undermine the added value new diagnostics of low complexity have for recipients and providers. We had high confidence in the evidence contributing to these review findings. Implementation of new diagnostic technologies, like those considered in this review, will need to tackle the challenges identified in this review including weak infrastructure and systems, and insufficient data on ground level realities prior and during implementation, as well as problems of conflicts of interest in order to ensure equitable use of resources." @default.
• W4224616384 created "2022-04-27" @default.
• W4224616384 creator A5015042879 @default.
• W4224616384 creator A5030946982 @default.
• W4224616384 creator A5031264217 @default.
• W4224616384 creator A5032995468 @default.
• W4224616384 creator A5040828153 @default.
• W4224616384 creator A5044462827 @default.
• W4224616384 creator A5086982928 @default.
• W4224616384 date "2022-04-26" @default.
• W4224616384 modified "2023-10-03" @default.
• W4224616384 title "Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views" @default.
• W4224616384 cites W1509910826 @default.
• W4224616384 cites W1545013510 @default.
• W4224616384 cites W1939705008 @default.
• W4224616384 cites W1979290264 @default.
• W4224616384 cites W1988898295 @default.
• W4224616384 cites W1999073290 @default.
• W4224616384 cites W2001681951 @default.
• W4224616384 cites W2022626126 @default.
• W4224616384 cites W2039970658 @default.
• W4224616384 cites W2042680533 @default.
• W4224616384 cites W2046731030 @default.
• W4224616384 cites W2047629101 @default.
• W4224616384 cites W2048864461 @default.
• W4224616384 cites W2074922906 @default.
• W4224616384 cites W2098269352 @default.
• W4224616384 cites W2101079712 @default.
• W4224616384 cites W2107112569 @default.
• W4224616384 cites W2109305774 @default.
• W4224616384 cites W2111321335 @default.
• W4224616384 cites W2112022845 @default.
• W4224616384 cites W2131434481 @default.
• W4224616384 cites W2132314077 @default.
• W4224616384 cites W2143025214 @default.
• W4224616384 cites W2153070779 @default.
• W4224616384 cites W2156312523 @default.
• W4224616384 cites W2162327774 @default.
• W4224616384 cites W2163831866 @default.
• W4224616384 cites W2163916310 @default.
• W4224616384 cites W2167313647 @default.
• W4224616384 cites W2200389916 @default.
• W4224616384 cites W2213610248 @default.
• W4224616384 cites W2252874986 @default.
• W4224616384 cites W2277206534 @default.
• W4224616384 cites W2293334163 @default.
• W4224616384 cites W2402129219 @default.
• W4224616384 cites W2415583474 @default.
• W4224616384 cites W2472138188 @default.
• W4224616384 cites W2494040287 @default.
• W4224616384 cites W2539447011 @default.
• W4224616384 cites W2558254411 @default.
• W4224616384 cites W2559832962 @default.
• W4224616384 cites W2560931542 @default.
• W4224616384 cites W2571286810 @default.
• W4224616384 cites W2605625811 @default.
• W4224616384 cites W2735519709 @default.
• W4224616384 cites W2740162871 @default.
• W4224616384 cites W2746906473 @default.
• W4224616384 cites W2753268266 @default.
• W4224616384 cites W2755424060 @default.
• W4224616384 cites W2764187398 @default.
• W4224616384 cites W2768015269 @default.
• W4224616384 cites W2784472800 @default.
• W4224616384 cites W2784670569 @default.
• W4224616384 cites W2790629966 @default.
• W4224616384 cites W2791523882 @default.
• W4224616384 cites W2792643538 @default.
• W4224616384 cites W2794300909 @default.
• W4224616384 cites W2795404224 @default.
• W4224616384 cites W2799666976 @default.
• W4224616384 cites W2807629398 @default.
• W4224616384 cites W2810885659 @default.
• W4224616384 cites W2886924776 @default.
• W4224616384 cites W2891125414 @default.
• W4224616384 cites W2905997739 @default.
• W4224616384 cites W2909936536 @default.
• W4224616384 cites W2912453786 @default.
• W4224616384 cites W2914167105 @default.
• W4224616384 cites W2915717366 @default.
• W4224616384 cites W2923781086 @default.
• W4224616384 cites W2940692714 @default.
• W4224616384 cites W2944040453 @default.
• W4224616384 cites W2944295219 @default.
• W4224616384 cites W2945770533 @default.
• W4224616384 cites W2946144676 @default.
• W4224616384 cites W2950500516 @default.
• W4224616384 cites W2952033053 @default.
• W4224616384 cites W2961945895 @default.
• W4224616384 cites W2965471365 @default.
• W4224616384 cites W2982248582 @default.
• W4224616384 cites W2988432882 @default.
• W4224616384 cites W2990768519 @default.
• W4224616384 cites W2993046886 @default.
• W4224616384 cites W2998495454 @default.
• W4224616384 cites W3006976811 @default.
• W4224616384 cites W3009073698 @default.
• W4224616384 cites W3011475793 @default.
• W4224616384 cites W3014849329 @default.
• W4224616384 cites W3028408134 @default.

• next